Biomea Fusion (BMEA) announced its presentations at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management in Singapore, 18-20 November. Biomea will showcase three oral ...

GSA Capital Partners LLP lowered its stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) by 36.8% during the third quarter, according to the company in its most recent disclosure with ...

On Tuesday, Truist Securities adjusted its stance on Biomea Fusion Inc. (NASDAQ:BMEA) stock, moving from a Buy to a Hold rating. This decision comes in the wake of a clinical hold... On Monday, H ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Icovamenib, a menin inhibitor from Biomea Fusion, is in early clinical development in both liquid and solid tumors. Other companies developing small molecule menin inhibitors include Johnson ...

Featured here, the Income Statement (earnings report) for Biomea Fusion Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and ...